Arvinas Inc (ARVN) valuation
Arvinas P/E ratio history
Arvinas trades at 32.8 times its earnings over the last twelve months.
| Fiscal year ended | Price | EPS | P/E |
|---|---|---|---|
| Dec 31, 2025 | $11.86 | -$1.14 | n/m |
| Dec 31, 2024 | $19.17 | -$2.77 | n/m |
| Dec 31, 2023 | $41.16 | -$6.62 | n/m |
| Dec 31, 2022 | $34.21 | -$5.31 | n/m |
| Dec 31, 2021 | $82.14 | -$3.82 | n/m |
| Dec 31, 2020 | $84.93 | -$3.01 | n/m |
| Dec 31, 2019 | $41.09 | -$2.14 | n/m |
| Dec 31, 2018 | $12.85 | — | n/m |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Arvinas valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| ArvinasARVN | $507M | 32.8 | — | 1.6 |
| Ideaya BiosciencesIDYA | $2.81B | — | — | 12.0 |
| ExelixisEXEL | $17.2B | 20.7 | 16.8 | 6.9 |
| Alnylam PharmaceuticalsALNY | $22.1B | 41.5 | 14.9 | 4.4 |
| BioNTechBNTX | $22.3B | — | — | 7.2 |
| IncyteINCY | $24.4B | 64.0 | 16.2 | 4.1 |
| InsmedINSM | $24.6B | — | — | 16.2 |
| CibusCBRS | $24.7B | — | — | — |
| BiogenBIIB | $37.5B | 109.3 | 16.6 | 3.6 |
| Peer median | 52.8 | 16.4 | 6.9 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: ARVN financials · ARVN returns
No forecast, no recommendation. This page describes Arvinas Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.